Dominique Valteau-Couanet
Institut Gustave Roussy
184 Papers
880 Citations
Dominique Valteau-Couanet is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 40, co-authored 167 publications. Previous affiliations of Dominique Valteau-Couanet include Centre national de la recherche scientifique & Necker-Enfants Malades Hospital.
Chat about Author
Papers
Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy
Hervé Rubie,Carole Coze,Dominique Plantaz,Caroline Munzer,Anne-Sophie Defachelles,Christophe Bergeron,Caroline Thomas,Pascal Chastagner,Dominique Valteau-Couanet,Jean Michon,Véronique Mosseri,Olivier Hartmann +11 more
TL;DR: Primary low-dose chemotherapy without anthracyclines is efficient in about half of the infants presenting with an unresectable NB and no N-myc amplification, allowing excellent survival rates without jeopardising their long-term outcome even for nonresponding patients who received standard regimen.
41
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
Lucas Moreno,Dongjing Guo,Meredith S. Irwin,Frank Berthold,Michael D. Hogarty,Takehiko Kamijo,Daniel A. Morgenstern,Claudia Pasqualini,Shifra Ash,Ulrike Pötschger,Ruth Ladenstein,Dominique Valteau-Couanet,Susan L. Cohn,Andrew D.J. Pearson,Wendy B. London +14 more
TL;DR: The objective was to identify prognostic biomarkers and apply them in a nomogram to identify the subgroup of ultra‐high‐risk patients at highest risk of disease progression/death, for whom novel frontline therapy is urgently needed.
41
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Lucas Moreno,H.N. Caron,Birgit Geoerger,Angelika Eggert,Gudrun Schleiermacher,Penelope Brock,Dominique Valteau-Couanet,Louis Chesler,Johannes H. Schulte,Katleen De Preter,Jan J. Molenaar,Alexander Schramm,Martin Eilers,Tom Van Maerken,John Inge Johnsen,Michelle D. Garrett,Sally L. George,Deborah A. Tweddle,Per Kogner,Frank Berthold,Jan Koster,Giuseppe Barone,Elizabeth R Tucker,Lynley V. Marshall,Ralf Herold,Jaroslav Sterba,Koen Norga,Gilles Vassal,Andrew D.J. Pearson +28 more
TL;DR: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation, and will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Dominique Valteau-Couanet,C. Faucher,Anne Auperin,Jean Michon,Noel-Jean Milpied,Jean-Michel Boiron,J. H. Bourhis,Christian Gisselbrecht,J P Vernant,Antonella Pinna,B Bendahmane,F Delabarre,Ellen Benhamou +12 more
TL;DR: Clinical and cost arguments favour the initiation of G-CSF on day 5 in adults with haematological malignancies or solid tumours, and the same policy could be applied in children given that clinical management is easier and costs are similar.
33
The right to be forgotten: a change in access to insurance and loans after childhood cancer?
Agnès Dumas,Agnès Dumas,Rodrigue S. Allodji,Rodrigue S. Allodji,Brice Fresneau,Brice Fresneau,Dominique Valteau-Couanet,Chiraz El-Fayech,Hélène Pacquement,Anne Laprie,Tan Dat Nguyen,Pierre-Yves Bondiau,Ibrahima Diallo,Ibrahima Diallo,Catherine Guibout,Catherine Guibout,Carole Rubino,Carole Rubino,Nadia Haddy,Nadia Haddy,Odile Oberlin,Gilles Vassal,Florent de Vathaire,Florent de Vathaire +23 more
TL;DR: It was showed that the financial burden of cancer can extend decades after diagnosis and Disclosure of childhood cancer to the insurer and amputation surgery were negatively associated with insurance accessibility, even when controlling for age, gender, education, health-related unemployment, familial situation, and severe or life-threatening conditions.
31